aTYR PHARMA (ATYR) Change in Cash (2014 - 2026)

aTYR PHARMA (ATYR) has reported Change in Cash for 13 consecutive years, with $5.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Change in Cash fell 20.02% year-over-year to $5.8 million; the trailing twelve-month figure through Jun 2026 stood at -$2.4 million (down 123.5% YoY), and the FY2025 full-year result was -$1.0 million, up 91.45% from the prior year.
• Change in Cash climbed to $5.8 million in Q2 2026 per ATYR's latest filing, from -$1.2 million in the prior quarter.
• Across five years, Change in Cash topped out at $12.8 million in Q4 2023 and bottomed at -$16.0 million in Q1 2024.
• Historically, Change in Cash has averaged $851055.6 across 5 years, with a median of $286000.0 in 2022.
• The sharpest annual moves came in 2023 and 2025: Change in Cash tumbled 1012.43% in 2023, then soared 2375.39% in 2025.
• Over 5 years, Change in Cash stood at -$7.5 million in 2022, then soared by 271.63% to $12.8 million in 2023, then sank by 102.96% to -$378000.0 in 2024, then soared by 1188.89% to $4.1 million in 2025, then soared by 41.93% to $5.8 million in 2026.
• According to Business Quant data, Change in Cash over the past three periods registered $5.8 million, -$1.2 million, and $4.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.